The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EBMT 2020 | IV daratumumab in R/R myeloma: bodyweight analysis
Maria-Victoria Mateos, MD, PhD, University Hospital of Salamanca, Salamanca, Spain, discusses the Phase III COLUMBA (NCT03277105) study evaluating subcutaneous intravenous (IV) daratumumab in relapsed/refractory (R/R) multiple myeloma patients, specifically discussed is the results of the bodyweight subgroup analysis. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
